A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation

Prostaglandin E1 (PGE1) has been reported to maintain adequate oxygenation among patients under 60% FiO one-lung ventilation (OLV). This research aimed to explore whether PGE1 is safe in pulmonary shunt and oxygenation under 40% FiO OLV and provide a reference concentration of PGE1. Totally 90 esophageal cancer patients treated with thoracotomy were enrolled in this study, randomly divided into three groups (n = 30/group): Group A (60% FiO and 0.1 µg/kg PGE1), Group B (40% FiO and 0.1 µg/kg PGE1), and Group C (40% FiO , 0.2 µg/kg PGE1). Primary outcomes were oxygenation and pulmonary shunt during OLV. Secondary outcomes included oxidative stress after OLV. During OLV, patients in Group C and B had lower levels of PaO , SaO , SpO , MAP, and Qs/Qt than those in Group A (P